Investigational New Drugs

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Investigational New Drugs - Tập 41 - Trang 541-550 - 2023
Minhong Tang, John Crown, Michael J Duffy
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both are thus attractive targets for new anticancer therapies. Historically, however, both genes have proved challenging to target and currently there is no approved therapy against either. The aim of this study was to investigate the effect of the mutant p53 reactivating drug, COTI-2 on MYC. Total MYC, pSer62 MYC and pThr...... hiện toàn bộ
Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
Investigational New Drugs - Tập 20 - Trang 183-194 - 2002
William D. Figg, Erwin A. Kruger, Douglas K. Price, Sonia Kim, William D. Dahut
Prostate cancer is the most frequentlydiagnosed malignancy and the second mostcommon cause of cancer-related death in menin the United States. Unfortunately, atthe current time, no curative treatmentsare available for metastatic prostatecancer. As is the case for most solidtumors, the recruitment of blood vessels(angiogenesis) is key for the progressionand metastasis of prostate cancer. Inhibition...... hiện toàn bộ
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma
Investigational New Drugs - Tập 24 - Trang 89-94 - 2006
Karl D. Lewis, John A. Thompson, Jeffrey S. Weber, William A Robinson, Steven O'Day, Jose Lutzky, Sewa S. Legha, Simon Floret, Francis Ruvuna, Rene Gonzalez
Metastatic melanoma continues to be a very difficult disease to treat. Options are limited and often have very little impact on the course of the disease. The objective of the current study was to evaluate the efficacy and safety of continuously administered Apomine (SR-45023A), a novel bisphosphonate, in patients with previously treated metastatic malignant melanoma. Adult patients with previousl...... hiện toàn bộ
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors
Investigational New Drugs - - 2010
Roos L. Oostendorp, Petronella O. Witteveen, Brian Schwartz, Liia D. Vainchtein, Margaret Schot, A. Nol, Hilde Rosing, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Nghiên cứu giai đoạn II về pyrazoloacridine (NSC#366140) ở bệnh nhân ung thư vú di căn Dịch bởi AI
Investigational New Drugs - Tập 29 - Trang 347-351 - 2009
Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab, Eric H. Kraut
Mục đích: Pyrazoloacridine (PZA) là một tác nhân nghiên cứu có khả năng liên kết với axit nucleic, ức chế hoạt động của các enzym topoisomerase 1 và 2. Chúng tôi đã tiến hành một nghiên cứu lâm sàng giai đoạn II để xác định hiệu quả và độc tính của PZA ở bệnh nhân ung thư vú di căn (MBC). Thiết kế nghiên cứu: Trong nghiên cứu đa trung tâm giai đoạn II này, bệnh nhân được điều trị với không quá một...... hiện toàn bộ
#Pyrazoloacridine #ung thư vú di căn #nghiên cứu lâm sàng #độc tính #điều trị hóa trị
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Investigational New Drugs - Tập 34 - Trang 740-749 - 2016
J. E. Grilley-Olson, P. L. Bedard, A. Fasolo, M. Cornfeld, L. Cartee, A. R. Abdul Razak, L.-A. Stayner, Y. Wu, R. Greenwood, R. Singh, C. B. Lee, J. Bendell, H. A. Burris, G. Del Conte, C. Sessa, J. R. Infante
Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. Patients and Methods Patients with advanced solid tumors received escalating doses of GSK458 (once or twice daily, and continuous or in...... hiện toàn bộ
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients
Investigational New Drugs - Tập 33 Số 3 - Trang 755-760 - 2015
Satoru Miura, Kyoichi Kaira, Rieko Kaira, Hiroaki Akamatsu, Akira Ono, Takehito Shukuya, Asuka Tsuya, Yukiko Nakamura, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto
Evaluation of amonafide in disseminated malignant melanoma
Investigational New Drugs - Tập 11 - Trang 223-226 - 1993
Milan Slavik, Kenneth J. Kopecky, Vernon Sondak, John B. Craig, Michael K. Samson
Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study of AMF in disseminated malignant melanoma. Twenty patients, eleven males and nine females, with biopsy proven malignant melanoma, performance status 0–2; median age 59 (range 29–74), and no previous chemotherapy, were treated with AMF 300 m...... hiện toàn bộ
Mitoxantrone hydrochloride (NSC-310739) in lymphoma
Investigational New Drugs - Tập 1 - Trang 65-70 - 1983
Charles A. Coltman, Terri M. McDaniel, Stanley P. Balcerzak, Francis S. Morrison, Daniel D. Von Hoff
The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was...... hiện toàn bộ
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer
Investigational New Drugs - Tập 7 - Trang 71-81 - 1989
Muhyi Al-Sarraf
While it is estimated to be one of the most prevalent cancers in the world, cancer of the head and neck is an uncommon malignant tumor in the United States and accounts for only 5% of all malignancies [1]. Head and neck cancer is a term that encompasses heterogeneous groups of patients. The most common histologic type is the squamous cell carcinoma. Cancer of the oral cavity is the most common sit...... hiện toàn bộ
Tổng số: 2,526   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10